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Oseltamivir- and 
Amantadine-
Resistant Inﬂ  uenza 
Virus A (H1N1)
To the Editor: We previously re-
ported detection of double resistance to 
oseltamivir and amantadine of inﬂ  uenza 
virus A (H1N1) in Hong Kong during 
the ﬁ  rst half of 2008 (1). Three different 
strains of A/Hong Kong/2652/2006-
like (clade 2C) viruses that carried 
the S31N mutation in the matrix (M2) 
gene associated with amantadine re-
sistance acquired a neuraminidase 
(NA) gene with CAT→TAT change at 
position 274 through either reassort-
ment with an oseltamivir-resistant A/
Brisbane/59/2007-like (clade 2B) virus 
or spontaneous H274Y mutation in the 
NA gene. A clade 2C strain resistant to 
both oseltamivir and amantadine also 
was detected in Cambodia in 2007 (2).
From July 2008 through Decem-
ber 2008, we continued to monitor 
antiviral susceptibility of all inﬂ  u-
enza A (H1N1) viruses in our labo-
ratory, using previously described 
methods (1). Resistance to oselta-
mivir increased from 16.9% in July 
to 97.8% in December (Table). Se-
quencing of the hemagglutinin (HA) 
gene showed that, beginning in Oc-
tober, A/Brisbane/59/2007-like clade 
2B virus had overtaken A/Hong 
Kong/2652/2006-like clade 2C virus 
to become the predominating circulat-
ing inﬂ  uenza A virus (H1N1) in Hong 
Kong. Of 916 isolates, 6 (0.7%), iso-
lated from July through September 
2008, were resistant to both amanta-
dine and oseltamivir. Genetic analysis 
showed that 5 were similar to those 
we described previously, 4 were A/
Hong Kong/2652/2006-like clade 2C 
viruses with spontaneous H274Y mu-
tation in the NA gene, and 1 was a 
clade 2C virus but acquired a clade 
2B NA gene carrying the H274Y mu-
tation. The sixth double-resistant vi-
rus was an A/Brisbane/59/2007-like 
clade 2B virus with a spontaneous 
S31N mutation in the M2 gene. No 
epidemiologic link was detectable 
between these viruses. From October 
through December 2008, no double-
resistant viruses were detected.
From January through June 2009, 
A/Brisbane/59/2007-like clade 2B vi-
rus continued to be the predominating 
strain. Of the total 1,537 inﬂ  uenza vi-
rus A (H1N1) isolates tested during the 
period, 1,509 (98.2%) were resistant 
to oseltamivir. Of the 1,509 oseltami-
vir-resistant isolates tested from April 
through June 2009, 50 (3.3%) also 
were resistant to amantadine (Table). 
Nucleotide sequencing of the HA, NA, 
and M2 genes was performed on all 50 
oseltamivir- and amantadine-resistant 
viruses. All were A/Brisbane/59/2007-
like clade 2B viruses that had acquired 
an M2 gene carrying the S31N mutation 
by reassortment with an amantadine-
resistant A/Hong Kong/2652/2006-
like clade 2C virus. Nucleotide se-
quencing of the other 5 internal genes 
(nonstructural, nucleoprotein, poly-
merase acidic, polymerase basic 1, 
and polymerase basic 2 proteins) was 
performed on 2 double-resistant strains 
isolated in April and on 3 isolated in 
June. Sequence comparison showed 
that 1 virus in April, in addition to ac-
quiring an M2 gene, acquired a non-
structural protein gene from an A/
Hong Kong/2652/2006-like clade 2C 
virus. All the viruses were susceptible 
to zanamivir and were not associated 
with unusual severity of disease.
Along with pandemic (H1N1) 
2009, seasonal inﬂ  uenza viruses con-
tinue to circulate in Hong Kong (3). 
An alarming proportion of the cir-
culating seasonal inﬂ  uenza  A  virus 
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Table. Prevalence of oseltamivir-resistant and amantadine- and oseltamivir-resistant influenza A virus (H1N1) detected in Hong Kong,
with clade designations, July 2008–June 2009 
Date detected
No. isolates 
tested
No. (%) isolates 
oseltamivir resistant
No. (%) isolates oseltamivir 
and amantadine resistant
Predominating influenza A virus (H1N1) clade, 
no. identified/total no. sequenced (%)
2008 Jul 462 78 (16.9) 4 (5.1) Clade 2C, 104/182 (57.1)
2008 Aug 313 45 (14.4) 1 (2.2) Clade 2C, 51/95 (53.7)
2008 Sep 61 21 (34.4) 1 (4.8) Clade 2B, 20/39 (51.3)
2008 Oct 19 13 (68.4) 0 Clade 2B, 13/16 (81.3)
2008 Nov 16 15 (93.8) 0 Clade 2B, 16/16 (100)
2008 Dec 45 44 (97.8) 0 Clade 2B, 41/41 (100)
2009 Jan 327 313 (95.7) 0 Clade 2B, 90/104 (86.5)
2009 Feb 769 755 (98.2) 0 Clade 2B, 138/153 (90.2)
2009 Mar 279 279 (100) 0 Clade 2B, 61/61 (100)
2009 Apr 63 63 (100) 2 (3.2) Clade 2B, 18/18 (100)
2009 May 22 22 (100) 2 (9.1) Clade 2B, 7/7 (100)
2009 Jun 77 77 (100) 46 (59.7) Clade 2B, 55/55 (100)LETTERS
(H1N1) became resistant to both os-
eltamivir and amantadine in a short 
span of 1 month. Oseltamivir-resistant 
A/Brisbane/59/2007-like clade 2B vi-
rus that had reassorted with A/Hong 
Kong/2652/2006-like clade 2C virus 
had apparently spread in the commu-
nity and to other regions of the world. 
The possibility of reassortment with 
pandemic (H1N1) 2009 virus is a ma-
jor concern. Resistance to oseltamivir 
of pandemic (H1N1) 2009 virus will 
compromise its use in treatment and 
render the billion-dose stockpile use-
less. Although the recently detected 
oseltamivir-resistant pandemic (H1N1) 
2009 virus in Hong Kong was not a re-
assortant virus (4,5), we will continue 
to closely monitor antiviral drug resis-
tance among circulating viruses, includ-
ing pandemic (H1N1) 2009 virus and 
seasonal inﬂ  uenza virus A (H1N1), as 
well as inﬂ  uenza A (H3N2) viruses, to 
track how antiviral resistance evolves.
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Pandemic (H1N1) 
2009 Reinfection, 
Chile
To the Editor: Since March 
2009, inﬂ  uenza A pandemic (H1N1) 
2009 has spread worldwide (1), and 
in South America, Chile was 1 of the 
countries most affected by the pan-
demic, with 21.4 cases among every 
1,000 persons. Treatment guidelines 
in Chile recommended antiviral drug 
treatment with oseltamivir or zana-
mivir for 5 days for all patients with 
conﬁ  rmed or suspected virus subtype 
H1N1 infection (2). In persons with 
seasonal inﬂ  uenza, speciﬁ  c antibody 
responses reach peak titers by 4 weeks 
after infection and confer protection 
against the infecting strain and close-
ly related strains (3). Reinfection is 
rarely seen in nonpandemic inﬂ  uenza 
A. We report on 3 patients with con-
ﬁ  rmed inﬂ  uenza A pandemic (H1N1) 
2009 reinfection after successful treat-
ment with oseltamivir.
Patient 1, a healthy 14-year-old 
girl, had fever, sore throat, and nasal 
congestion on clinical examination. 
Pandemic (H1N1) 2009 infection 
was diagnosed by viral culture and 
conﬁ  rmed by PCR speciﬁ  c for sub-
type H1N1 (LightMix Kit Inf A swine 
H1; TIB MOLBIOL, Berlin, Germa-
ny, for Roche Diagnostic, Indianapo-
lis, IN, Light Cycler 2.0 instrument). 
The patient received oseltamivir, and 
symptoms resolved 48 hours after 
treatment. Twenty days later, fever, 
muscle aches, and vomiting devel-
oped in the patient. Inﬂ  uenza A virus 
was isolated by viral culture. The pa-
tient received a preliminary diagnosis 
of seasonal inﬂ  uenza and was treated 
with amantadine. She recovered from 
the infection before PCR results con-
ﬁ   rmed it was caused by pandemic 
(H1N1) 2009 virus. 
Patient 2, a 62-year-old woman, 
experienced a high fever, cough, and 
nasal congestion during a prolonged 
hospitalization for bowel resection 
after intestinal ischemia. Pandemic 
(H1N1) 2009 was conﬁ  rmed by PCR 
and viral culture. Oseltamivir was 
administered 5 days after the onset 
of symptoms, and the symptoms re-
solved within the following 5 days. 
The patient had a new episode of fe-
ver, productive cough, and bronchial 
obstruction 2 weeks later while still 
hospitalized. Culture results were 
positive for inﬂ  uenza, and PCR results 
were positive for pandemic (H1N1) 
2009. The patient was again treated 
with oseltamivir, and PCR results 
were negative for inﬂ  uenza after 48 
hours of antiviral treatment.
Patient 3, a previously healthy 
38-year-old man, underwent mitral 
and aortic valve replacement while 
hospitalized for acute mitral and aor-
tic endocarditis due to Staphylococcus 
aureus. Eleven days after surgery, he 
had a sore throat, nasal congestion, 
cough, and low-grade fever. PCR test 
results were positive for pandemic 
(H1N1) 2009. The patient received 
oseltamivir, and respiratory symp-
toms resolved within 5 days. He was 
discharged from the hospital but was 
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